Interleukin-6 ＂Trans-Signaling＂ and Ischemic Vascular Disease: The Important Role of Soluble gp130

Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian r...

Full description

Saved in:
Bibliographic Details
Published in:Mediators of Inflammation 2017-01, Vol.2017 (2017), p.1-6
Main Authors: Morieri, Mario Luca, Zuliani, Giovanni, Passaro, Angelina
Format: Article
Language:English
Subjects:
Animals
Atherosclerosis
Atherosclerosis - immunology
Atherosclerosis - metabolism
Binding sites
Blood circulation disorders
Cardiovascular disease
Cardiovascular Diseases - immunology
Cardiovascular Diseases - metabolism
Cytokine Receptor gp130 - metabolism
Cytokines
Glycoproteins
Health aspects
Humans
Hypotheses
Inflammation
Inflammation - immunology
Inflammation - metabolism
Insulin resistance
Interleukin-6
Interleukin-6 - metabolism
Metabolism
Models, Biological
Physiological aspects
Prevention
Proteins
Recruitment
Review
Risk Factors
Rodents
Signal transduction
Signal Transduction - physiology
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a673t-72f03a1675bdb0a90bb6d1085b81ea1eaef3217e067a6199056955a8b57c36193
cites cdi_FETCH-LOGICAL-a673t-72f03a1675bdb0a90bb6d1085b81ea1eaef3217e067a6199056955a8b57c36193
container_end_page 6
container_issue 2017
container_start_page 1
container_title Mediators of Inflammation
container_volume 2017
creator Morieri, Mario Luca
Zuliani, Giovanni
Passaro, Angelina
description Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset of myocardial infarction. At the same time, IL-6 pathway is divided into two arms: classic signaling (effective in hepatocytes and leukocytes) and trans-signaling (with ubiquitous activity). Trans-signaling is known to be inhibited by the circulating soluble glycoprotein 130 (sgp130). In animal and in vitro models, trans-signaling inhibition with sgp130 antibody clearly shows a beneficial effect on inflammatory disease and atherosclerosis. Conversely, epidemiological data report inconsistent results between sgp130 levels and CV risk factors as well as CV outcome. We have reviewed the literature to understand the role of sgp130 and to find the evidence in favor of or against a possible clinical application of sgp130 treatment in the prevention of cardiovascular disease.
doi_str_mv 10.1155/2017/1396398
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f89e50b69fd7452d9eb2617e0fd55f27</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A547075908</galeid><airiti_id>P20160527003_201712_201811120011_201811120011_1_6_013</airiti_id><doaj_id>oai_doaj_org_article_f89e50b69fd7452d9eb2617e0fd55f27</doaj_id><sourcerecordid>A547075908</sourcerecordid><originalsourceid>FETCH-LOGICAL-a673t-72f03a1675bdb0a90bb6d1085b81ea1eaef3217e067a6199056955a8b57c36193</originalsourceid><addsrcrecordid>eNqNks1u1DAQgCMEoqVw44wicUGCtB47_usBqSp_K1UC0YWr5ST2rpesvdgJiCvPxTvxCjjdpWURB5RItiefP8czUxQPAR0DUHqCEfATIJIRKW4Vh1AzVoFgcLs4RJLhShIKB8W9lFYIIVrX4m5xgAWmiPL6sLAzP5jYm_GT8xUrf_74Po_ap-rSLbzunV_kSKl9V85SuzRr15YfdWrHXsfyhUtGJ3NazpemnK03IQ7aD-X70Jsy2PIy9GOTp4sNEHS_uGN1n8yD3XhUfHj1cn7-prp4-3p2fnZRacbJUHFsEdHAOG26BmmJmoZ1gARtBBidX2MJBm4Q45qBlIgySakWDeUtyQFyVMy23i7oldpEt9bxmwraqatAiAul4-Da3igrpKGoYdJ2vKa4k6bBbHLbjlKLeXY937o2Y7M2XWv8EHW_J93_4t1SLcIXRQniCEEWPNkJYvg8mjSotUut6XvtTRiTAsEJx7XENKOP_0JXYYy5AhOV08EpBXFDLXS-gPM25HPbSarOaM0RpxJN1PE_qPx0U_2CN9bl-N6GZ9sNbQwpRWOv7whITT2mph5Tux7L-KM_83IN_26qDDzdAkvnO_3V_afOZMZYfUODEPkPM3CxBbSLbnA3mXmXPQxRnJNNrpyAp0EAAM75h_0FKKZyUcgvLUX2Kw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867575518</pqid></control><display><type>article</type><title>Interleukin-6 ＂Trans-Signaling＂ and Ischemic Vascular Disease: The Important Role of Soluble gp130</title><source>PubMed Central Free</source><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Morieri, Mario Luca ; Zuliani, Giovanni ; Passaro, Angelina</creator><contributor>Vaccarezza, Mauro</contributor><creatorcontrib>Morieri, Mario Luca ; Zuliani, Giovanni ; Passaro, Angelina ; Vaccarezza, Mauro</creatorcontrib><description>Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset of myocardial infarction. At the same time, IL-6 pathway is divided into two arms: classic signaling (effective in hepatocytes and leukocytes) and trans-signaling (with ubiquitous activity). Trans-signaling is known to be inhibited by the circulating soluble glycoprotein 130 (sgp130). In animal and in vitro models, trans-signaling inhibition with sgp130 antibody clearly shows a beneficial effect on inflammatory disease and atherosclerosis. Conversely, epidemiological data report inconsistent results between sgp130 levels and CV risk factors as well as CV outcome. We have reviewed the literature to understand the role of sgp130 and to find the evidence in favor of or against a possible clinical application of sgp130 treatment in the prevention of cardiovascular disease.</description><identifier>ISSN: 0962-9351</identifier><identifier>EISSN: 1466-1861</identifier><identifier>DOI: 10.1155/2017/1396398</identifier><identifier>PMID: 28250574</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Animals ; Atherosclerosis ; Atherosclerosis - immunology ; Atherosclerosis - metabolism ; Binding sites ; Blood circulation disorders ; Cardiovascular disease ; Cardiovascular Diseases - immunology ; Cardiovascular Diseases - metabolism ; Cytokine Receptor gp130 - metabolism ; Cytokines ; Glycoproteins ; Health aspects ; Humans ; Hypotheses ; Inflammation ; Inflammation - immunology ; Inflammation - metabolism ; Insulin resistance ; Interleukin-6 ; Interleukin-6 - metabolism ; Metabolism ; Models, Biological ; Physiological aspects ; Prevention ; Proteins ; Recruitment ; Review ; Risk Factors ; Rodents ; Signal transduction ; Signal Transduction - physiology ; Studies</subject><ispartof>Mediators of Inflammation, 2017-01, Vol.2017 (2017), p.1-6</ispartof><rights>Copyright © 2017 Mario Luca Morieri et al.</rights><rights>COPYRIGHT 2017 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2017 Mario Luca Morieri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 Mario Luca Morieri et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a673t-72f03a1675bdb0a90bb6d1085b81ea1eaef3217e067a6199056955a8b57c36193</citedby><cites>FETCH-LOGICAL-a673t-72f03a1675bdb0a90bb6d1085b81ea1eaef3217e067a6199056955a8b57c36193</cites><orcidid>0000-0001-6864-0547</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1867575518/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1867575518?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28250574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Vaccarezza, Mauro</contributor><creatorcontrib>Morieri, Mario Luca</creatorcontrib><creatorcontrib>Zuliani, Giovanni</creatorcontrib><creatorcontrib>Passaro, Angelina</creatorcontrib><title>Interleukin-6 ＂Trans-Signaling＂ and Ischemic Vascular Disease: The Important Role of Soluble gp130</title><title>Mediators of Inflammation</title><addtitle>Mediators Inflamm</addtitle><description>Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset of myocardial infarction. At the same time, IL-6 pathway is divided into two arms: classic signaling (effective in hepatocytes and leukocytes) and trans-signaling (with ubiquitous activity). Trans-signaling is known to be inhibited by the circulating soluble glycoprotein 130 (sgp130). In animal and in vitro models, trans-signaling inhibition with sgp130 antibody clearly shows a beneficial effect on inflammatory disease and atherosclerosis. Conversely, epidemiological data report inconsistent results between sgp130 levels and CV risk factors as well as CV outcome. We have reviewed the literature to understand the role of sgp130 and to find the evidence in favor of or against a possible clinical application of sgp130 treatment in the prevention of cardiovascular disease.</description><subject>Animals</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - immunology</subject><subject>Atherosclerosis - metabolism</subject><subject>Binding sites</subject><subject>Blood circulation disorders</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - immunology</subject><subject>Cardiovascular Diseases - metabolism</subject><subject>Cytokine Receptor gp130 - metabolism</subject><subject>Cytokines</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Inflammation</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Insulin resistance</subject><subject>Interleukin-6</subject><subject>Interleukin-6 - metabolism</subject><subject>Metabolism</subject><subject>Models, Biological</subject><subject>Physiological aspects</subject><subject>Prevention</subject><subject>Proteins</subject><subject>Recruitment</subject><subject>Review</subject><subject>Risk Factors</subject><subject>Rodents</subject><subject>Signal transduction</subject><subject>Signal Transduction - physiology</subject><subject>Studies</subject><issn>0962-9351</issn><issn>1466-1861</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks1u1DAQgCMEoqVw44wicUGCtB47_usBqSp_K1UC0YWr5ST2rpesvdgJiCvPxTvxCjjdpWURB5RItiefP8czUxQPAR0DUHqCEfATIJIRKW4Vh1AzVoFgcLs4RJLhShIKB8W9lFYIIVrX4m5xgAWmiPL6sLAzP5jYm_GT8xUrf_74Po_ap-rSLbzunV_kSKl9V85SuzRr15YfdWrHXsfyhUtGJ3NazpemnK03IQ7aD-X70Jsy2PIy9GOTp4sNEHS_uGN1n8yD3XhUfHj1cn7-prp4-3p2fnZRacbJUHFsEdHAOG26BmmJmoZ1gARtBBidX2MJBm4Q45qBlIgySakWDeUtyQFyVMy23i7oldpEt9bxmwraqatAiAul4-Da3igrpKGoYdJ2vKa4k6bBbHLbjlKLeXY937o2Y7M2XWv8EHW_J93_4t1SLcIXRQniCEEWPNkJYvg8mjSotUut6XvtTRiTAsEJx7XENKOP_0JXYYy5AhOV08EpBXFDLXS-gPM25HPbSarOaM0RpxJN1PE_qPx0U_2CN9bl-N6GZ9sNbQwpRWOv7whITT2mph5Tux7L-KM_83IN_26qDDzdAkvnO_3V_afOZMZYfUODEPkPM3CxBbSLbnA3mXmXPQxRnJNNrpyAp0EAAM75h_0FKKZyUcgvLUX2Kw</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Morieri, Mario Luca</creator><creator>Zuliani, Giovanni</creator><creator>Passaro, Angelina</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6864-0547</orcidid></search><sort><creationdate>20170101</creationdate><title>Interleukin-6 ＂Trans-Signaling＂ and Ischemic Vascular Disease: The Important Role of Soluble gp130</title><author>Morieri, Mario Luca ; Zuliani, Giovanni ; Passaro, Angelina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a673t-72f03a1675bdb0a90bb6d1085b81ea1eaef3217e067a6199056955a8b57c36193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - immunology</topic><topic>Atherosclerosis - metabolism</topic><topic>Binding sites</topic><topic>Blood circulation disorders</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - immunology</topic><topic>Cardiovascular Diseases - metabolism</topic><topic>Cytokine Receptor gp130 - metabolism</topic><topic>Cytokines</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Inflammation</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Insulin resistance</topic><topic>Interleukin-6</topic><topic>Interleukin-6 - metabolism</topic><topic>Metabolism</topic><topic>Models, Biological</topic><topic>Physiological aspects</topic><topic>Prevention</topic><topic>Proteins</topic><topic>Recruitment</topic><topic>Review</topic><topic>Risk Factors</topic><topic>Rodents</topic><topic>Signal transduction</topic><topic>Signal Transduction - physiology</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morieri, Mario Luca</creatorcontrib><creatorcontrib>Zuliani, Giovanni</creatorcontrib><creatorcontrib>Passaro, Angelina</creatorcontrib><collection>Chinese Electronic Periodical Services (CEPS)</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Mediators of Inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morieri, Mario Luca</au><au>Zuliani, Giovanni</au><au>Passaro, Angelina</au><au>Vaccarezza, Mauro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-6 ＂Trans-Signaling＂ and Ischemic Vascular Disease: The Important Role of Soluble gp130</atitle><jtitle>Mediators of Inflammation</jtitle><addtitle>Mediators Inflamm</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>0962-9351</issn><eissn>1466-1861</eissn><abstract>Inflammation plays a major role in the onset of cardiovascular disease (CVD). Interleukine-6 (IL-6) is a multifunctional cytokine involved both in the beneficial acute inflammatory response and in the detrimental chronic low-grade systemic inflammation. Large genetic human studies, using Mendelian randomization approaches, have clearly showed that IL-6 pathway is causally involved in the onset of myocardial infarction. At the same time, IL-6 pathway is divided into two arms: classic signaling (effective in hepatocytes and leukocytes) and trans-signaling (with ubiquitous activity). Trans-signaling is known to be inhibited by the circulating soluble glycoprotein 130 (sgp130). In animal and in vitro models, trans-signaling inhibition with sgp130 antibody clearly shows a beneficial effect on inflammatory disease and atherosclerosis. Conversely, epidemiological data report inconsistent results between sgp130 levels and CV risk factors as well as CV outcome. We have reviewed the literature to understand the role of sgp130 and to find the evidence in favor of or against a possible clinical application of sgp130 treatment in the prevention of cardiovascular disease.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>28250574</pmid><doi>10.1155/2017/1396398</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6864-0547</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0962-9351
ispartof Mediators of Inflammation, 2017-01, Vol.2017 (2017), p.1-6
issn 0962-9351
1466-1861
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_f89e50b69fd7452d9eb2617e0fd55f27
source PubMed Central Free; Wiley Online Library Open Access; Publicly Available Content Database
subjects Animals
Atherosclerosis
Atherosclerosis - immunology
Atherosclerosis - metabolism
Binding sites
Blood circulation disorders
Cardiovascular disease
Cardiovascular Diseases - immunology
Cardiovascular Diseases - metabolism
Cytokine Receptor gp130 - metabolism
Cytokines
Glycoproteins
Health aspects
Humans
Hypotheses
Inflammation
Inflammation - immunology
Inflammation - metabolism
Insulin resistance
Interleukin-6
Interleukin-6 - metabolism
Metabolism
Models, Biological
Physiological aspects
Prevention
Proteins
Recruitment
Review
Risk Factors
Rodents
Signal transduction
Signal Transduction - physiology
Studies
title Interleukin-6 ＂Trans-Signaling＂ and Ischemic Vascular Disease: The Important Role of Soluble gp130
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A14%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-6%20%EF%BC%82Trans-Signaling%EF%BC%82%20and%20Ischemic%20Vascular%20Disease:%20The%20Important%20Role%20of%20Soluble%20gp130&rft.jtitle=Mediators%20of%20Inflammation&rft.au=Morieri,%20Mario%20Luca&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=0962-9351&rft.eissn=1466-1861&rft_id=info:doi/10.1155/2017/1396398&rft_dat=%3Cgale_doaj_%3EA547075908%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a673t-72f03a1675bdb0a90bb6d1085b81ea1eaef3217e067a6199056955a8b57c36193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1867575518&rft_id=info:pmid/28250574&rft_galeid=A547075908&rft_airiti_id=P20160527003_201712_201811120011_201811120011_1_6_013&rfr_iscdi=true